Evidence mapPaperPMID 39162986Full record

ReviewPharmacological reports : PR2024

The possible pathogenesis of liver fibrosis: therapeutic potential of natural polyphenols.

Chengu Niu, Jing Zhang, Patrick I Okolo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chengu NiuInternal medicine residency program, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY, 14621, USA. chenguniu@gmail.com.ORCID http://orcid.org/0000-0001-5610-5897
Jing ZhangRainier Springs Behavioral Health Hospital, 2805 NE 129th St, Vancouver, WA, 98686, USA.
Patrick I OkoloDivision of Gastroenterology, Rochester General Hospital, Rochester, NY, 14621, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is the formation of a fibrous scar resulting from chronic liver injury, independently from etiology. Although many of the mechanical details remain unknown, activation of hepatic stellate cells (HSCs) is a central driver of liver fibrosis. Extracellular mechanisms such as apoptotic bodies, paracrine stimuli, inflammation, and oxidative stress are critical in activating HSCs. The potential for liver fibrosis to reverse after removing the causative agent has heightened interest in developing antifibrotic therapies. Polyphenols, the secondary plant metabolites, have gained attention because of their health-beneficial properties, including well-recognized antioxidant and anti-inflammatory activities, in the setting of liver fibrosis. In this review, we present an overview of the mechanisms underlying liver fibrosis with a specific focus on the activation of resident HSCs. We highlight the therapeutic potential and promising role of natural polyphenols to mitigate liver fibrosis pathogenesis, focusing on HSCs activation. We also discuss the translational gap from preclinical findings to clinical treatments involved in natural polyphenols in liver fibrosis.

Indexed as

Hepatic Stellate CellsLiver CirrhosisPolyphenolsAnimalsAnti-Inflammatory AgentsAntioxidantsHumansOxidative StressAnti-Inflammatory AgentsAntioxidantsPolyphenolsFibrogenic cytokinesHepatic stellate cellsLiver fibrosisNatural polyphenolsPre-clinical studies

Identifiers

PMID39162986

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.